Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS · NASDAQ Global Select
-$0.02 today
Vol 0.12M · Avg 0.10M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:MENS · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$4.7M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.09, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $100.0K -16.7% | $120.0K -5.5% | $127.0K +4.1% | $122.0K +0.8% | $121.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$100.0K +16.7% | -$120.0K +5.5% | -$127.0K -4.1% | -$122.0K -0.8% | -$121.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $731.0K -21.1% | $927.0K -13.4% | $1.1M -17.0% | $1.3M -17.3% | $1.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $1.8M +57.3% | $1.1M -34.6% | $1.7M +12.2% | $1.5M +82.1% | $845.0K | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $2.5M +21.9% | $2.1M -26.5% | $2.8M -1.1% | $2.8M +17.7% | $2.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $100.0K -16.7% | $120.0K -5.5% | $127.0K +3.3% | $123.0K +0.8% | $122.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$2.5M -34.5% | -$1.9M +47.0% | -$3.5M +38.8% | -$5.7M -77.2% | -$3.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$2.6M -26.8% | -$2.1M +26.5% | -$2.8M +1.1% | -$2.8M -17.7% | -$2.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $610.0K +8614.3% | $7.0K -87.5% | $56.0K +1020.0% | $5.0K -16.7% | $6.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $2.5M +145.3% | $1.0M +36.7% | $757.0K -1.0% | $765.0K -8.4% | $835.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$2.1M -114.3% | -$963.0K +39.9% | -$1.6M +57.8% | -$3.8M -111.9% | -$1.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$4.7M -54.7% | -$3.0M +31.4% | -$4.4M +33.6% | -$6.6M -57.9% | -$4.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$4.7M -54.7% | -$3.0M +31.4% | -$4.4M +33.6% | -$6.6M -57.9% | -$4.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 -61.2% | -$0 +31.4% | -$0 +33.6% | -$0 -58.0% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 -61.2% | -$0 +31.4% | -$0 +33.6% | -$0 -58.0% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $73.0M -4.0% | $76.0M +0.0% | $76.0M +0.0% | $76.0M +0.0% | $76.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $73.0M -4.0% | $76.0M +0.0% | $76.0M +0.0% | $76.0M +0.0% | $76.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.19B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.58B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.34B
Legend Biotech Corporation
NASDAQ:LEGN
$5.14B
Travere Therapeutics, Inc.
NASDAQ:TVTX
$5.06B
Celcuity Inc.
NASDAQ:CELC
$4.26B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.22B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.19B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.73B
Ascentage Pharma Group International
NASDAQ:AAPG
$404.16M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does MENS generate?
Jyong Biotech Ltd. Ordinary Shares (MENS) reported $0.00 of revenue in fiscal 2025.
Is MENS profitable?
Jyong Biotech Ltd. Ordinary Shares (MENS) reported -$4,671,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.